These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 15916855)

  • 1. Neoadjuvant taxanes in the treatment of non-metastatic breast cancer: a systematic review.
    Trudeau M; Sinclair SE; Clemons M;
    Cancer Treat Rev; 2005 Jun; 31(4):283-302. PubMed ID: 15916855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
    Goble S; Bear HD
    Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer.
    Nowak AK; Wilcken NR; Stockler MR; Hamilton A; Ghersi D
    Lancet Oncol; 2004 Jun; 5(6):372-80. PubMed ID: 15172358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
    Freedman OC; Verma S; Clemons MJ
    Cancer Treat Rev; 2005 Feb; 31(1):1-17. PubMed ID: 15707700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer.
    Estévez LG; Gradishar WJ
    Clin Cancer Res; 2004 May; 10(10):3249-61. PubMed ID: 15161677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant Therapy for HER2-positive Breast Cancer.
    Wuerstlein R; Harbeck N
    Rev Recent Clin Trials; 2017; 12(2):81-92. PubMed ID: 28164759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
    Sparano JA
    Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New combination chemotherapy regimens in the primary treatment of operable breast cancer].
    Conti F; Sergi D; Foggi P; Abbate MI; Lopez M
    Clin Ter; 2007; 158(1):55-75. PubMed ID: 17405660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current and future roles of neoadjuvant chemotherapy in operable breast cancer.
    Kim R; Osaki A; Toge T
    Clin Breast Cancer; 2005 Aug; 6(3):223-32; discussion 233-4. PubMed ID: 16137432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant chemotherapy in breast cancer.
    Charfare H; Limongelli S; Purushotham AD
    Br J Surg; 2005 Jan; 92(1):14-23. PubMed ID: 15635596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary (neoadjuvant) chemotherapy with docetaxel in breast cancer.
    Gradishar WJ
    Clin Breast Cancer; 2001 Oct; 2 Suppl 1():S31-5. PubMed ID: 11970742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Taxanes as primary chemotherapy for early breast cancer: meta-analysis of randomized trials.
    Cuppone F; Bria E; Carlini P; Milella M; Felici A; Sperduti I; Nisticò C; Terzoli E; Cognetti F; Giannarelli D
    Cancer; 2008 Jul; 113(2):238-46. PubMed ID: 18470908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lessons from the neoadjuvant setting on how best to choose adjuvant therapies.
    von Minckwitz G; Loibl S; Maisch A; Untch M
    Breast; 2011 Oct; 20 Suppl 3():S142-5. PubMed ID: 22015282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response rates of taxane rechallenge in metastatic breast cancer patients previously treated with adjuvant taxanes.
    Kucukoztas N; Oguz A; Rahatli S; Altundag O; Altundag K
    J BUON; 2016; 21(5):1076-1081. PubMed ID: 27837607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Neoadjuvant treatment of early breast cancer: new drugs contribution].
    Giacchetti S; Cuvier C; Hocini H; Bourstyn E; de Roquancourt A; Espié M
    Bull Cancer; 2004 Dec; 91 Suppl 4():S232-8. PubMed ID: 15899614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant chemotherapy for operable breast cancer: is this the future?
    Mamounas EP
    Clin Breast Cancer; 2003 Apr; 4 Suppl 1():S10-9. PubMed ID: 12756074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Use of Taxotere in neoadjuvant therapy of breast cancer].
    Semiglazov VV; Donskikh RV; Semiglazova TIu; Bozhok AA; Matsko DE
    Vopr Onkol; 2011; 57(5):645-50. PubMed ID: 22238937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant chemotherapy for locally advanced breast cancer in a malaysian tertiary hospital.
    Azrif M; Ibrahim J; Aslan NM; Fong KV; Ismail F
    Asian Pac J Cancer Prev; 2011; 12(1):157-62. PubMed ID: 21517250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anthracycline-Free Neoadjuvant Chemotherapy Ensures Higher Rates of Pathologic Complete Response in Breast Cancer.
    De Iuliis F; Salerno G; Corvino R; D'Aniello D; Cefalì K; Taglieri L; Lanza R; Scarpa S
    Clin Breast Cancer; 2017 Feb; 17(1):34-40. PubMed ID: 27435626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The curability of breast cancer and the treatment of advanced disease.
    Guarneri V; Conte PF
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S149-61. PubMed ID: 15107948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.